Odimma is a French biotech company with a unique approach in active personalized cancer immunotherapy.
Immunotherapy has revolutionized the treatment of many advanced cancers. Despite this amazing achievement, significant clinical benefits are still limited to 10 to 30% of patients.
Odimma believes in the future of precision medicine, and leverages recent advances in the field of immuno-oncology to amplify the efficacy of current therapies, improving lives and making each patient unique.
By harnessing the ability of the patient’s own immune system to specifically recognize non-self-targets displayed by the tumor, also called neoantigens, Odimma has designed a next-generation personalized immunization platform that brings a sustainable therapeutic solution to fight the most hard-to-treat cancers.
Carried by a team of experts and a supportive environment, we are now preparing our upcoming entry in the clinic
Immunotherapy has revolutionized the treatment of many advanced cancers. Despite this amazing achievement, significant clinical benefits are still limited to 10 to 30% of patients.
Odimma believes in the future of precision medicine, and leverages recent advances in the field of immuno-oncology to amplify the efficacy of current therapies, improving lives and making each patient unique.
By harnessing the ability of the patient’s own immune system to specifically recognize non-self-targets displayed by the tumor, also called neoantigens, Odimma has designed a next-generation personalized immunization platform that brings a sustainable therapeutic solution to fight the most hard-to-treat cancers.
Carried by a team of experts and a supportive environment, we are now preparing our upcoming entry in the clinic
Location: France, Grand Est, Illkirch-Graffenstaden
Employees: 1-10
Total raised: $2.21M
Founded date: 2017
Investors 1
| Date | Name | Website |
| 02.09.2021 | Capital Gr... | capitalgra... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 04.05.2023 | Seed | $2.21M | - |
Mentions in press and media 3
| Date | Title | Description |
| 04.05.2023 | France-based Odimma Therapeutics raises EUR 2 million in seed funding | Strasbourg, France-based biotechnology company specialising in personalized cancer immunotherapy, Odimma Therapeutics, raised EUR 2 million in seed funding. The round took place on May 2, 2023. Capital Grand Est, Alsace Business Angels, and... |
| 03.05.2023 | Odimma Therapeutics Secures €2M in Seed Funding | Odimma Therapeutics, a Strasbourg, France-based biotechnology company which specializes in personalized cancer immunotherapy, raised €2M in Seed funding. Backers included Capital Grand Est, Alsace Business Angels, Angels Santé, and BpiFranc... |
| 17.05.2022 | ABL AND ODIMMA THERAPEUTICS JOIN FORCES IN PERSONALIZED CANCER IMMUNOTHERAPY | PARIS, May 17, 2022 /PRNewswire/ -- ABL Europe (ABL), a pure play contract development and manufacturing organization (CDMO) specialized in development and manufacturing of virus for vaccine candidates, gene and cancer therapies and Odimma ... |